Product Information
OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB is a generic product labeled by Solco Healthcare US LLC, priced at $0.1650 per EA under NDC 43547039109. Its NADAC has been published 477 times since Aug 16, 2017.
FDA first approved this application on Apr 24, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB
olmesartan medoxomil and hydrochlorothiazideStrength
12.5; 20 mg/1; mg/1
Manufacturer
Solco Healthcare US LLCNDC
43547039109
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA207804FDA Approved
4/24/2017
TE Code
AB
On Market Since
4/24/2017
Pharmacological Classes
Price Statistics
The NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has been published 477 times since Aug 16, 2017, and over the history we have for it it has declined 14.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1650 per EA |
|---|---|
| All-time high | $0.6620 (Oct 14, 2020) |
| All-time low | $0.1437 (Oct 17, 2018) |
| 52-week high | $0.1842 |
| 52-week low | $0.1650 |
| Median price | $0.1965 |
| Average price | $0.2209 |
| Largest weekly change | +64.4% (Jun 17, 2020) |
| Weeks tracked | 477 |
| Tracking since | Aug 16, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Solco Healthcare US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olmesartan medoxomil and hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB, manufactured by Solco Healthcare US LLC, is $0.1650 per EA (NDC 43547039109), effective Sep 30, 2026.
How has the price of OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has declined 14.3%. It has been tracked across 477 weekly CMS publications since Aug 16, 2017.
What are the highest and lowest recorded NADAC prices for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
Since Aug 16, 2017, the NADAC for OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB has ranged from a low of $0.1437 (Oct 17, 2018) to a high of $0.6620 (Oct 14, 2020), with a median of $0.1965 per EA.
Are there cheaper alternatives to OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB?
OLMESARTAN-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB (NDC 43547039109) is labeled by Solco Healthcare US LLC, and CMS classifies it as a generic product.